Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic suppression of frequent premature ventricular complexes in asymptomatic patients
2021-002487-46Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bisoprolol, nebivolol, flecainide, verapamil, diltiazem and 3 more in Premature ventricular complexes (PVC) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Development of left ventricular dysfunction. Started Jan 2022; status: active.
02
Drugs
bisoprololnebivololflecainideverapamildiltiazem
03
Conditions
Premature ventricular complexes (PVC)
Beyond the preview
Go deeper on 2021-002487-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002487-46.